Skip to main content
. 2021 Dec 2;11(12):e048975. doi: 10.1136/bmjopen-2021-048975

Table 2.

Basic characteristics of the inclusion study

Study Male Female Open biopsy Partial resection Complete resection Experimental/control
Chinot et al10 282 (61.6)/
298 (64.4)
176 (38.4)/
165 (35.6)
60 (13.1)/
44 (9.5)
210 (45.9)/
223 (48.2)
188 (41.0)/
196 (42.3)
BEV+RT–TMZ/
Placebo+RT–TMZ
Qianru11 14/12 11/12 / 15/16 10/8 BEV+TMZ/TMZ
Herrlinger et al12 80 (69.0)/
34 (63.0)
36 (31.0)/
20 (37.0)
0/2 (;3.7) 58 (;50.0)/
27 (;50.0)
58 (50.0)/
25 (46.3)
BEV+IRI/TMZ
Gilbert et al13 / / / / / Bevacizumab/placebo
Chen et al14 30 (;53)/
45 (;57)/
15 (;65)
57/79/23
27 (;47)/
34 (;43)/
8 (;35)
34 (;60)/
44 (;56)/
14 (;61)
20 (;35)/
33 (;42)/
9 (;39)
3 (;5)/
2 (;2)/
0 (;0)
Bevacizumab monotherapy
/bevacizumab combination
/non-bevacizumab
Hualong et al15 19/18 12/13 / / / TMZ+BEV/TMZ
Zhixian et al16 22 18 / 18 22 BEV+TMZ/Gamma knife+TMZ
Jiaqi et al17 16/14 11/13 / / / TMZ+BEV/TMZ
Albert et al18 31/40 39/70 2/23 40/40 28/47 RT+TMZ+BV/RT/TMZ
Chauffert et al19 26/23 34/37 / / / BEV+IRI/TMZ+RT
Balana et al20 31/25 17/20 42/35 / / TMZ+BEV/TMZ

BEV, bevacizumab; BV, Bevacizumab; IRI, Irinotecan; RT, radiotherapy; TMZ, temozolomide.